London, UK – 29 September 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, announces, in accordance with Listing Rule 9.6.18, that…
Oxford BioMedica plc Interim Results for the six months ended 30 June 2016 Oxford, UK – 13 September 2016: Oxford BioMedica plc (LSE: OXB), (“OXB” or “the Group”) a leading…
– World-class centre for lentiviral gene therapy bioprocessing and process development approved and fully operational – Capital expenditure and expansion of Group’s facilities now complete Oxford, UK – 28 July…
Oxford, UK – 6 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that Tim Watts, Chief Financial Officer, will…
Oxford, UK – 7 June 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces that it has signed a new non-exclusive…
Unique combination of Oxford BioMedica’s LentiVector® delivery platform and Green Cross LabCell’s NK cell platform to generate a pipeline of differentiated products in cancer Oxford, UK & Seoul, Korea – 2…
Oxford, UK – 17 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, is pleased to announce that it has appointed Jefferies…
Oxford, UK – 12 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces today that Dr Paul Blake will leave the…
Oxford, UK – 6 May 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today announces that new data has been presented from…
Encore is InterCall’s recording replay service and provides the opportunity to listen to the Event for those who were unable to attend it live or who would like to listen…
London, UK – 26 April 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), a leading gene and cell therapy company, today announces the appointment of Stuart Henderson as a…
Oxford, UK – 7 March 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, today announced a new and expanded collaboration with…